Our drug candidate slows and even stops the progression of PD by protecting dopaminergic neurons. It accomplishes this by inhibiting the FAF1 proteins that promote cell death—an approach we’ve shown to be effective in animal models and are beginning to test in human proof of concept trials.
Unique Opportunities with KM-819
New Target & Mechanism
KM-819 is the first disease modifying drug candidate for PD that targets and inhibits FAF1 proteins.
Neuroprotection
Where other PD treatments focus on addressing the symptoms of cell death, KM-819 prevents the cells from dying in the first place, slowing or even stopping progression altogether.
Excellent Safety Profile
KM-819 has completed long-term safety toxicology and a phase I clinical study, demonstrating an acceptable safety profile for long-term administration in patients.
